Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Elevance Health Inc (NYSE: ELV) closed at $294.43 up 0.67% from its previous closing price of $292.48. In other words, the price has increased by $0.67 from its previous closing price. On the day, 2.37 million shares were traded. ELV stock price reached its highest trading level at $298.9 during the session, while it also had its lowest trading level at $291.94.
Ratios:
For a deeper understanding of Elevance Health Inc’s stock, let’s take a closer look at its various ratios. In the meantime, Its Debt-to-Equity ratio is 0.69 whereas as Long-Term Debt/Eq ratio is at 0.64.
On July 18, 2025, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $310.
Robert W. Baird Downgraded its Outperform to Neutral on April 15, 2025, while the target price for the stock was maintained at $529.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 18 ’25 when BOUDREAUX GAIL bought 8,500 shares for $286.94 per share. The transaction valued at 2,438,951 led to the insider holds 151,020 shares of the business.
Kaye Mark sold 4,588 shares of ELV for $1,949,074 on Apr 24 ’25. The EVP & CFO now owns 18,977 shares after completing the transaction at $424.82 per share. On Apr 24 ’25, another insider, Kaye Mark, who serves as the Officer of the company, bought 4,588 shares for $424.81 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELV now has a Market Capitalization of 66299158528 and an Enterprise Value of 61822246912. As of this moment, Elevance’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.53, and their Forward P/E ratio for the next fiscal year is 9.15. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.84. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.35 while its Price-to-Book (P/B) ratio in mrq is 1.51. Its current Enterprise Value per Revenue stands at 0.327 whereas that against EBITDA is 6.517.
Stock Price History:
The Beta on a monthly basis for ELV is 0.59, which has changed by -0.45649046 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, ELV has reached a high of $567.26, while it has fallen to a 52-week low of $273.71. The 50-Day Moving Average of the stock is -12.31%, while the 200-Day Moving Average is calculated to be -23.79%.
Shares Statistics:
For the past three months, ELV has traded an average of 2.36M shares per day and 2481640 over the past ten days. A total of 224.84M shares are outstanding, with a floating share count of 224.79M. Insiders hold about 0.17% of the company’s shares, while institutions hold 92.45% stake in the company. Shares short for ELV as of 1753920000 were 2840716 with a Short Ratio of 1.20, compared to 1751241600 on 2539048. Therefore, it implies a Short% of Shares Outstanding of 2840716 and a Short% of Float of 1.26.
Dividends & Splits
According to the company, the forward annual dividend rate for ELV is 6.68, from 6.68 in the trailing year. Against a Trailing Annual Dividend Yield of 0.022839166The stock’s 5-year Average Dividend Yield is 1.22. The current Payout Ratio is 25.39% for ELV, which recently paid a dividend on 2025-06-10 with an ex-dividend date of 2025-09-10. Stock splits for the company last occurred on 2005-06-01 when the company split stock in a 2:1 ratio.
Earnings Estimates
At present, 15.0 analysts are actively evaluating the performance of Elevance Health Inc (ELV) in the stock market.The consensus estimate for the next quarter is $4.1, with high estimates of $4.54 and low estimates of $1.96.
Analysts are recommending an EPS of between $30.32 and $28.77 for the fiscal current year, implying an average EPS of $29.88. EPS for the following year is $32.98, with 21.0 analysts recommending between $39.23 and $26.97.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $49.23B this quarter.It ranges from a high estimate of $50.2B to a low estimate of $48.66B. As of the current estimate, Elevance Health Inc’s year-ago sales were $44.72BFor the next quarter, 10 analysts are estimating revenue of $49.41B. There is a high estimate of $50.9B for the next quarter, whereas the lowest estimate is $47.78B.
A total of 12 analysts have provided revenue estimates for ELV’s current fiscal year. The highest revenue estimate was $199.04B, while the lowest revenue estimate was $194.96B, resulting in an average revenue estimate of $196.9B. In the same quarter a year ago, actual revenue was $175.2BBased on 10 analysts’ estimates, the company’s revenue will be $208.33B in the next fiscal year. The high estimate is $213.85B and the low estimate is $200.55B.
